News >

Navitoclax Activity Confirmed in Ruxolitinib-Resistant Myelofibrosis

Caroline Seymour
Published: Thursday, Jan 30, 2020

Jacqueline S. Garcia, MD

Jacqueline S. Garcia, MD

The addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib (Jakafi) led to a clinically meaningful reduction in spleen volume and improvement in symptoms in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib, according to results of a phase II study presented at the 2019 ASH Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication